Welcome to our dedicated page for Redhill Biopharm SEC filings (Ticker: RDHL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The RedHill Biopharma Ltd. (Nasdaq: RDHL) SEC filings page on Stock Titan provides centralized access to the company’s Form 20-F annual reports and Form 6-K current reports, which together document its regulatory, clinical, commercial and financing activities. As a foreign private issuer focused on gastrointestinal diseases, infectious diseases and oncology, RedHill uses Form 6-K extensively to furnish press releases and other information to the U.S. Securities and Exchange Commission.
In these filings, investors can review detailed disclosures about Talicia®, RedHill’s FDA-approved oral therapy for Helicobacter pylori infection in adults, including its indication, QIDP-based market exclusivity, patent coverage and ex-U.S. licensing arrangements. Filings also describe the company’s late-stage development programs: opaganib (ABC294640), a sphingosine kinase-2 selective inhibitor with anticancer, anti-inflammatory and antiviral activity; RHB-102 (Bekinda®), an extended-release ondansetron formulation for multiple gastrointestinal and oncology-support indications; RHB-204, an optimized formulation of RHB-104 for Crohn’s disease and pulmonary nontuberculous mycobacteria disease; and RHB-107 (upamostat), a host-directed serine protease inhibitor in late-stage development for non-hospitalized symptomatic COVID-19 and other conditions.
RedHill’s Form 6-K reports also cover capital markets and financing transactions, such as at-the-market offering programs, purchase agreements for American Depositary Shares, and amendments to ownership thresholds. Additional filings document Nasdaq listing compliance matters, including notifications related to the minimum stockholders’ equity requirement and subsequent confirmation of regained compliance, as well as legal proceedings like New York Supreme Court judgments and Korean court attachment orders in the Kukbo dispute.
Stock Titan’s interface is designed to surface these filings as they are furnished to EDGAR and to pair them with AI-powered summaries that explain the key points of lengthy documents. Users can quickly identify items such as quarterly and interim financial information, registration statement incorporations by reference, and governance or financing updates, while drilling down into full-text filings when more detail is needed.
RedHill Biopharma’s 2025 annual report highlights severe liquidity pressure and a going concern warning. Net cash used in operating activities was $9.7 million in 2025, leaving cash, cash equivalents, short‑term investments and restricted cash of only $4.1 million as of December 31, 2025, which management states is insufficient to fund operations and obligations for the next year.
The company still carries legacy Movantik® liabilities of about $1.5 million and obligations of $5.7 million under the Global Termination Agreement, alongside other overdue payables. RedHill depends on raising significant additional capital and negotiating deferred payments to continue operating, while commercialization prospects now rely heavily on Talicia® via Talicia Holdings and its collaboration with Cumberland.
Management also reports that internal control over financial reporting remained ineffective as of December 31, 2025 due to an unresolved material weakness affecting allowance for deductions from revenues, raising continued reporting and governance risk.
RedHill Biopharma reported 2025 results marked by a reshaped Talicia business, new partnerships and a small overall loss. On a continuing basis, revenue was $0.3 million, with an operating loss of $7.9 million and net loss from continuing operations of $8.1 million.
Talicia commercial operations moved into Talicia Holdings Inc., a 70%-owned joint venture with Cumberland, which generated discontinued-operation net income of $7.7 million. A licensing deal with Hyloris for RHB‑102 (Bekinda) carries up to $60 million in potential milestones plus royalties.
Total assets rose to $25.3 million and equity improved to $4.3 million, while year-end cash was $4.1 million after $9.7 million of operating cash use, partly offset by $7.3 million from equity financing. The company also secured a $10.5 million final court judgment against Kukbo, not yet reflected as a receivable, and advanced multiple late-stage GI and oncology programs.
RedHill Biopharma Ltd. Chief Operating Officer Gilead Raday reported compensation-related share activity tied to restricted share unit vesting. A trustee sold 1,574 American Depositary Shares (ADS) solely to cover tax withholding, at $0.8001 per ADS, equal to 15,740,000 ordinary shares based on 10,000 ordinary shares per ADS. Following this sale, Raday’s direct holdings in ordinary shares were 261,060,000. He also exercised derivative rights over 30,780,000 ADS representing 30,780,000 underlying ordinary shares, leaving 76,150,000 ADS directly held. Footnotes state the transaction was executed under a sell-to-cover policy and did not represent a discretionary trade by Raday.
RedHill Biopharma reports new preclinical data on its investigational drug opaganib, presented in two posters at the 2026 American Association for Cancer Research meeting. In neuroblastoma models, opaganib appeared to enhance the effect of an oxaliplatin plus doxorubicin chemotherapy combination by destabilizing n-Myc and increasing cancer cell apoptosis.
In triple-negative breast cancer cell models, pretreatment with opaganib followed by low-dose diABZI potentiated STING-mediated signaling, suggesting a possible boost to anti-tumor immunity. Opaganib has FDA Orphan Drug and Rare Pediatric Disease designations for neuroblastoma and is already in a Bayer-supported Phase 2 study in metastatic castrate-resistant prostate cancer.
RedHill Biopharma Ltd. reported receiving a notice from Nasdaq that its American Depositary Shares have failed to meet the $1.00 minimum bid price requirement for 30 consecutive business days, from February 20, 2026 to April 2, 2026.
Under Nasdaq Listing Rule 5810(c)(3)(A), the company has 180 calendar days, until October 5, 2026, to regain compliance by having its ADS bid price close at or above $1.00 for at least 10 consecutive business days. RedHill’s ADSs remain listed on the Nasdaq Capital Market, and the company states that its operations are not affected by this notice at this time.
RedHill Biopharma Ltd. director Tsimchi Ofer filed an initial Form 3 reporting his equity holdings in the company. The filing shows direct ownership of 146,250,000 Ordinary Shares and 3,644 American Depositary Shares (ADSs), which are convertible into Ordinary Shares at the holder’s election with no expiration date.
Ofer also reports 14,625 unvested restricted share units, each linked to one ADS and settled in Ordinary Shares. In addition, he holds stock options over 150,000, 90,000 and 180,000 Ordinary Shares, with exercise prices of $5,000, $4,870 and $7,080 per ADS, expiring on May 6, 2029, March 25, 2030 and April 28, 2031, respectively.
RedHill Biopharma Ltd. director and Chief Commercial Officer Rick D. Scruggs filed an initial Form 3 disclosing his holdings in the company. As of the filing, he directly owns 312,500,000 Ordinary Shares, along with American Depositary Shares (ADSs) and equity awards linked to additional Ordinary Shares.
His equity-based compensation includes 31,250 unvested restricted share units, each tied to one ADS and settled in Ordinary Shares, plus 7,364 ADSs that are convertible at any time with no expiration date. He also holds fully vested stock options covering 750,000, 300,000, 70,000 and 840,000 Ordinary Shares, each granted under the RedHill 2010 Option Plan with exercise prices per ADS of $6,840, $7,000, $7,000 and $6,620, expiring between February 25, 2029 and July 25, 2031.
RedHill Biopharma Ltd. director Reed Kenneth filed an initial ownership report showing equity interests in the company. He holds 10,520 unvested restricted share units, each tied to one American Depositary Share and settled in ordinary shares, plus 2,583 ADSs that are convertible at any time and have no expiration date.
He also holds stock options to purchase 90,000 ordinary shares (equivalent to 9 ADSs) at an exercise price of $4,870 per ADS expiring on March 25, 2030, 150,000 ordinary shares (equivalent to 15 ADSs) at $7,000 per ADS expiring on May 6, 2029, and 250,000 ordinary shares (equivalent to 25 ADSs) at $6,620 per ADS expiring on July 25, 2031. These options are fully vested and exercisable.
RedHill Biopharma’s Chief Operating Officer Raday Gilead has filed an initial Form 3 reporting his equity holdings. He holds 30,758 unvested restricted share units, each linked to one American Depositary Share (ADS), and 4,537 ADSs that are convertible at any time with no expiration date.
The filing also lists several stock option grants to purchase Ordinary Shares: 250,000 and 400,000 shares with an exercise price of $5,000 per ADS, 600,000 shares at $4,870 per ADS, and 570,000 and 180,000 shares at $7,080 per ADS. Most option grants are described as fully vested and exercisable, with expirations between March 2028 and April 2031.
RedHill Biopharma Ltd. director Mamluk Roni has filed an initial ownership report detailing existing equity awards and share holdings. The filing shows 10,350 unvested restricted share units, each tied to one American Depositary Share (ADS). Each ADS represents 10,000 ordinary shares of RedHill Biopharma Ltd.
The RSUs are subject to time-based vesting conditions and are settled in ordinary shares. The report also discloses 1,350 ADSs that are convertible at any time at the holder’s election and have no expiration date. This Form 3 does not reflect new buy or sell transactions, only current beneficial ownership.